AARTIDRUGS

AARTI DRUGS

Small Cap BSE: 524348 NSE: AARTIDRUGS
₹463.9
15.25 (3.4%)
As on 30 September, 2022 | 02:00

Aarti Drugs Share Price

Aarti Drugs Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in AARTI DRUGS

Start SIP

Aarti Drugs Share Returns

  • Over 1 Month 7.41%
  • Over 3 Month 15.8%
  • Over 6 Month 10.24%
  • Over 1 Year -23.8%

Aarti Drugs Key Statistics

P/E Ratio 22.5
PEG Ratio -1
Market Cap Cr 4,296
Price to Book Ratio 4.1
EPS 21.1
Dividend 0.2
Relative Strength Index 56.48
Money Flow Index 53.79
MACD Signal 5.89
Average True Range 15.69

Aarti Drugs Investment Rating

  • Master Rating:
  • Aarti Drugs has an operating revenue of Rs. 2,530.65 Cr. on a trailing 12-month basis. An annual revenue growth of 16% is outstanding, Pre-tax margin of 11% is healthy, ROE of 19% is exceptional. The company has a reasonable debt to equity of 13%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 73 which is a FAIR score but needs to improve its earnings, a RS Rating of 40 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 125 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Aarti Drugs Financials
IndicatorJun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 551641593511506452
Operating Expenses Qtr Cr 496557503442432374
Operating Profit Qtr Cr 558491697478
Depreciation Qtr Cr 121212121212
Interest Qtr Cr 765544
Tax Qtr Cr 101420131513
Net Profit Qtr Cr 265356414650

Aarti Drugs Technicals

EMA & SMA

Current Price
463.9
15.25 (3.4%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 453.8
  • 50 Day
  • 444.7
  • 100 Day
  • 444.5
  • 200 Day
  • 461.32
  • 20 Day
  • 455.04
  • 50 Day
  • 442.06
  • 100 Day
  • 428.49
  • 200 Day
  • 460.73

Aarti Drugs Resistance and Support

PIVOT
₹443.12
Resistance
First Resistance 456.24
Second Resistance 463.82
Third Resistance 476.94
RSI 56.48
MFI 53.79
MACD Single Line 5.89
MACD 4.45
Support
First Resistance 435.54
Second Resistance 422.42
Third Resistance 414.84

Aarti Drugs Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 157,324 5,852,453 37.2
Week 224,897 7,100,011 31.57
1 Month 269,490 7,990,386 29.65
6 Month 169,086 5,562,925 32.9

Aarti Drugs Result Highlights

Aarti Drugs Synopsis

NSE-Medical-Diversified

Aarti Drugs Ltd is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 2251.17 Cr. and Equity Capital is Rs. 92.60 Cr. for the Year ended 31/03/2022. Aarti Drugs Ltd. is a Public Limited Listed company incorporated on 28/09/1984 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L37060MH1984PLC055433 and registration number is 055433.
Market Cap 4,296
Sales 2,297
Shares in Float 3.70
No of funds 70
Yield 0.22
Book Value 4.42
U/D Vol ratio 2.2
LTDebt / Equity 12
Alpha -0.08
Beta 0.8

Aarti Drugs

Owner NameJun-22Mar-22Dec-21Sep-21
Promoters 59.98%59.83%59.99%
Mutual Funds 2.68%2.62%2.2%
Insurance Companies 0.08%0.08%0.08%
Foreign Portfolio Investors 2.07%2.07%2.03%
Financial Institutions/ Banks
Individual Investors 32.16%32.02%32.85%
Others 3.03%3.38%2.85%

Aarti Drugs Management

Name Designation
Mr. Chandrakant V Gogri Chairman Emeritus
Mr. Prakash M Patil Chairman & M.D & CEO
Mr. Rashesh C Gogri Managing Director
Mr. Harshit M Savla Joint Managing Director
Mr. Harit P Shah Executive Director
Mr. Uday M Patil Executive Director
Mr. Neha R Gada Non Executive Director
CA. Navin C Shah Independent Director
Dr. Krishnacharya G Akamanchi Independent Director
Prof. Bhaskar N Thorat Independent Director
CA. Priti P Savla Independent Director

Aarti Drugs Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Aarti Drugs Corporate Action

Date Purpose Remarks
2022-07-27 Quarterly Results
2022-05-09 Audited Results
2022-01-31 Audited Results & Interim Dividend
2021-10-27 Quarterly Results
2021-07-27 Quarterly Results
Date Purpose Remarks
2022-02-10 INTERIM Rs.1.00 per share(10%)Interim Dividend

Aarti Drugs MF Shareholding

Name Amount(cr)
DSP Small Cap Fund Regular Plan Growth 8982
DSP Healthcare Fund Regular Growth 1161
DSP Value Fund Regular Plan Growth 602
Nippon India Nifty Smallcap 250 Index Fund Reg Gr 477
Motilal Oswal Nifty 500 Fund Regular Growth 348

Aarti Drugs FAQs

What is Share Price of Aarti Drugs ?

Aarti Drugs share price is ₹463 As on 30 September, 2022 | 01:46

What is the Market Cap of Aarti Drugs ?

The Market Cap of Aarti Drugs is ₹4295.7 Cr As on 30 September, 2022 | 01:46

What is the P/E ratio of Aarti Drugs ?

The P/E ratio of Aarti Drugs is 22.5 As on 30 September, 2022 | 01:46

What is the PB ratio of Aarti Drugs ?

The PB ratio of Aarti Drugs is 4.1 As on 30 September, 2022 | 01:46

Q1FY23